Andrew Leslie

Title: Andrew Leslie: Innovator in G Protein Research

Introduction

Andrew Leslie is a notable inventor based in Swindon, GB. He has made significant contributions to the field of biochemistry, particularly in the study of G proteins. With a total of 2 patents to his name, Leslie's work has implications for understanding cellular signaling mechanisms.

Latest Patents

Leslie's latest patents focus on the development of mutant heterotrimeric G protein alpha (Gα) subunits. The first patent describes a mutant that lacks at least one helix of the helical domain of the parent Gα subunit. This mutant is capable of binding to a G protein-coupled receptor (GPCR) without the need for a heterotrimeric G protein beta (Gβ) subunit and a heterotrimeric G protein gamma (Gγ) subunit. Additionally, the amino acid sequence of this mutant contains one or more mutations compared to the parent Gα subunit, which may include deletions, substitutions, or insertions.

Career Highlights

Throughout his career, Andrew Leslie has worked with prominent companies in the pharmaceutical and biotechnology sectors. He has been associated with Heptares Therapeutics Limited and Nxera Pharma UK Limited, where he has contributed to innovative research and development projects.

Collaborations

Leslie has collaborated with various professionals in his field, including Byron Carpenter and Rony Nehmé. These collaborations have likely enhanced his research and contributed to the advancement of G protein studies.

Conclusion

Andrew Leslie's work in the field of G proteins showcases his innovative spirit and dedication to scientific advancement. His patents reflect significant progress in understanding cellular signaling, which may have far-reaching implications in biochemistry and medicine.